RVL Pharmaceuticals plc (RVLP) financial statements (2022 and earlier)

Company profile

Business Address 400 CROSSING BOULEVARD
BRIDGEWATER, NJ 08807
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Receivables2,13326,41243,91456,424
Inventory, net of allowances, customer advances and progress billings83817,93421,30524,383
Inventory83817,93421,30524,383
Other undisclosed current assets56,408128,808107,41191,578
Total current assets:59,379173,154172,630172,385
Noncurrent Assets
Finance lease, right-of-use asset558 
Operating lease, right-of-use asset1,3682,7554,983
Property, plant and equipment721,88230,23831,263
Intangible assets, net (including goodwill)83,057166,613254,841591,245
Goodwill55,847100,855100,855100,855
Intangible assets, net (excluding goodwill)27,21065,758153,986490,390
Other noncurrent assets 373563752
Other undisclosed noncurrent assets78926,114  
Total noncurrent assets:85,291197,795290,625623,260
TOTAL ASSETS:144,670370,949463,255795,645
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities16,85554,28773,748112,500
Accounts payable3,7776,7688,49524,870
Accrued liabilities13,07747,51765,25387,237
Taxes payable12 394
Debt2,414402,1891,894
Other undisclosed current liabilities8391,457  
Total current liabilities:20,10855,78475,937114,394
Noncurrent Liabilities
Long-term debt and lease obligation592220,965271,110266,941
Long-term debt, excluding current maturities 219,525267,950266,803
Finance lease, liability 444
Capital lease obligations138
Operating lease, liability5921,4363,116
Liabilities, other than long-term debt2173441,50028,041
Accounts payable and accrued liabilities66  1,804
Deferred tax liabilities, net26,238
Deferred income tax liabilities1513441,500
Other undisclosed noncurrent liabilities47,020   
Total noncurrent liabilities:47,829221,309272,610294,982
Total liabilities:67,937277,093348,547409,376
Stockholders' equity
Stockholders' equity attributable to parent76,73393,856114,708386,269
Common stock833625518525
Additional paid in capital591,730548,070489,440489,950
Accumulated other comprehensive income (loss)1,700(2,229)(2,229)(1,846)
Accumulated deficit(517,530)(452,610)(373,021)(102,360)
Total stockholders' equity:76,73393,856114,708386,269
TOTAL LIABILITIES AND EQUITY:144,670370,949463,255795,645

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues17,501177,884240,031263,701
Cost of revenue
(Cost of Goods and Services Sold)
(3,618)(74,480)(111,630)(135,014)
Gross profit:13,883103,404128,401128,687
Operating expenses(102,273)(173,840)(409,096)(227,225)
Other undisclosed operating income5,636   
Operating loss:(82,754)(70,436)(280,695)(98,538)
Nonoperating income (expense)(1,333)546884(20,126)
Foreign currency transaction loss, before tax(2,229)   
Interest and debt expense(3,036)(14,396)(18,211)(876)
Loss from continuing operations before equity method investments, income taxes:(87,123)(84,286)(298,022)(119,540)
Other undisclosed income from continuing operations before income taxes4,589  876
Loss from continuing operations before income taxes:(82,534)(84,286)(298,022)(118,664)
Income tax benefit3154,69727,1219,268
Loss from continuing operations:(82,219)(79,589)(270,901)(109,396)
Income from discontinued operations13,867   
Loss before gain (loss) on sale of properties:(68,352)(79,589)(270,901)(109,396)
Other undisclosed net income3,432   
Net loss available to common stockholders, diluted:(64,920)(79,589)(270,901)(109,396)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(64,920)(79,589)(270,901)(109,396)
Comprehensive loss:(64,920)(79,589)(270,901)(109,396)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent3,929 (383)(1,213)
Comprehensive loss, net of tax, attributable to parent:(60,991)(79,589)(271,284)(110,609)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: